Population pharmacokinetics of valproic acid in pediatric patients with epilepsy: Considerations for dosing spinal muscular atrophy patients

Journal of Clinical Pharmacology

Volumn 52, Issue 11, 2012, Pages 1676-1688

  Williams, Jason H ^a   Jayaraman, Bhuvaneswari ^a   Swoboda, Kathryn J ^b   Barrett, Jeffrey S ^a  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

Pediatrics; pharmacokinetics; SMA; spinal muscular atrophy; valproic acid

Indexed keywords

VALPROIC ACID;

ADOLESCENT; ARTICLE; BENIGN CHILDHOOD EPILEPSY; CHILD; COMPARTMENT MODEL; DISTRIBUTION VOLUME; DRUG CAPSULE; DRUG CLEARANCE; DRUG DOSAGE FORM COMPARISON; DRUG EXPOSURE; DRUG FORMULATION; DRUG MONITORING; HUMAN; LEAN BODY WEIGHT; MAJOR CLINICAL STUDY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); SIMULATION; SPINAL MUSCULAR ATROPHY; SYRUP; TABLET FORMULATION;

ADOLESCENT; ANTICONVULSANTS; CAPSULES; CHILD; CHILD, PRESCHOOL; EPILEPSY; FEMALE; HUMANS; INFANT; MALE; MODELS, BIOLOGICAL; MUSCULAR ATROPHY, SPINAL; VALPROIC ACID;

EID: 84868007938     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270011428138     Document Type: Article

References (30)

1. Dutta S, Faught E, Limdi NA. Valproate protein binding following rapid intravenous administration of high doses of valproic acid in patients with epilepsy. J Clin Pharm Ther. 2007 ; 32: 365-371 (Pubitemid 47063160)
2. Botha JH, Gray AL, Miller R. A model for estimating individualized valproate clearance values in children. J Clin Pharmacol. 1995 ; 35: 1020-1024
3. Perucca E. Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience. CNS Drugs. 2002 ; 16: 695-714 (Pubitemid 35176854)
4. Chuang DM, Leng Y, Marinova Z, Kim HJ, Chiu CT. Multiple roles of HDAC inhibition in neurodegenerative conditions. Trends Neurosci. 2009 ; 32: 591-601
5. Michaelis M, Doerr HW, Cinatl J. Valproic acid as anti-cancer drug. Curr Pharm Des. 2007 ; 13: 3378-3393 (Pubitemid 350201672)
6. Marks PA. The clinical development of histone deacetylase inhibitors as targeted anticancer drugs. Expert Opin Investig Drugs. 19: 1049-1066
7. Lehrman G, Hogue IB, Palmer S, et al. Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet. 2005 ; 366: 549-555 (Pubitemid 41140329)
8. Swoboda KJ, Scott CB, Reyna SP, et al. Phase II open label study of valproic acid in spinal muscular atrophy. PLoS One. 2009 ; 4: e5268
9. Weihl CC, Connolly AM, Pestronk A. Valproate may improve strength and function in patients with type III/IV spinal muscle atrophy. Neurology. 2006 ; 67: 500-501 (Pubitemid 44214981)
10. Munster P, Marchion D, Bicaku E, et al. Clinical and biological effects of valproic acid as a histone deacetylase inhibitor on tumor and surrogate tissues: phase I/II trial of valproic acid and epirubicin/FEC. Clin Cancer Res. 2009 ; 15: 2488-2496
11. Swoboda KJ, Scott CB, Crawford TO, et al. SMA CARNI-VAL trial part I: double-blind, randomized, placebo-controlled trial of L-carnitine and valproic acid in spinal muscular atrophy. PLoS One. 2010 ; 5: e12140
12. Kissel JT, Scott CB, Reyna SP, et al. SMA CARNIVAL trial part II: a prospective, single-armed trial of L-carnitine and valproic acid in ambulatory children with spinal muscular atrophy. PLoS One. 2011 ; 6: e21296
13. Ramsay RE, Cantrell D, Collins SD, et al. Safety and tolerance of rapidly infused Depacon: a randomized trial in subjects with epilepsy. Epilepsy Res. 2003 ; 52: 189-201 (Pubitemid 36106564)
14. Cloyd JC, Dutta S, Cao G, Walch JK, Collins SD, Granneman GR. Valproate unbound fraction and distribution volume following rapid infusions in patients with epilepsy. Epilepsy Res. 2003 ; 53: 19-27 (Pubitemid 36170167)
15. Ette EI. Stability and performance of a population pharmacokinetic model. J Clin Pharmacol. 1997 ; 37: 486-495 (Pubitemid 27265649)
16. Dutta S, Reed RC. Distinct absorption characteristics of oral formulations of valproic acid/divalproex available in the United States. Epilepsy Res. 2007 ; 73: 275-283
17. Meibohm B, Laer S, Panetta JC, Barrett JS. Population pharmacokinetic studies in pediatrics: issues in design and analysis. AAPS J. 2005 ; 7: E475-487
18. Chiba K, Suganuma T, Ishizaki T, et al. Comparison of steady-state pharmacokinetics of valproic acid in children between monotherapy and multiple antiepileptic drug treatment. J Pediatr. 1985 ; 106: 653-658 (Pubitemid 15080565)
19. Cloyd JC, Fischer JH, Kriel RL, Kraus DM. Valproic acid pharmacokinetics in children. IV. Effects of age and antiepileptic drugs on protein binding and intrinsic clearance. Clin Pharmacol Ther. 1993 ; 53: 22-29 (Pubitemid 23036684)
20. Gal P, Oles KS, Gilman JT, Weaver R. Valproic acid efficacy, toxicity, and pharmacokinetics in neonates with intractable seizures. Neurology. 1988 ; 38: 467-471 (Pubitemid 18083690)
21. Park HM, Kang SS, Lee YB, et al. Population pharmacokinetics of intravenous valproic acid in Korean patients. J Clin Pharm Ther. 2002 ; 27: 419-425
22. Jiang DC, Wang L, Wang YQ, Li L, Lu W, Bai XR. Population pharmacokinetics of valproate in Chinese children with epilepsy. Acta Pharmacol Sin. 2007 ; 28: 1677-1684 (Pubitemid 47493299)
23. Serrano BB, Garcia Sanchez MJ, Otero MJ, Buelga DS, Serrano J, Dominguez-Gil A. Valproate population pharmacokinetics in children. J Clin Pharm Ther. 1999 ; 24: 73-80 (Pubitemid 29171682)
24. Hall K, Otten N, Johnston B, Irvine-Meek J, Leroux M, Seshia S. A multivariable analysis of factors governing the steady-state pharmacokinetics of valproic acid in 52 young epileptics. J Clin Pharmacol. 1985 ; 25: 261-268 (Pubitemid 15091099)
25. Dutta S, Reed RC. A multiphasic absorption model best characterizes gastrointestinal absorption of divalproex sodium extended-release tablets. J Clin Pharmacol. 2006 ; 46: 952-957 (Pubitemid 44050832)
26. Dutta S, Cloyd JC, Granneman GR, Collins SD. Oral/intravenous maintenance dosing of valproate following intravenous loading: a simulation. Epilepsy Res. 2003 ; 53: 29-38 (Pubitemid 36170168)
27. Reed RC, Dutta S. What is the best strategy for converting from twice-daily divalproex to a once-daily divalproex ER regimen? Examinations and answers via computer simulations. Clin Drug Investig. 2004 ; 24: 509-521 (Pubitemid 39273960)
28. Blanco-Serrano B, Otero MJ, Santos-Buelga D, Garcia-Sanchez MJ, Serrano J, Dominguez-Gil A. Population estimation of valproic acid clearance in adult patients using routine clinical pharmacokinetic data. Biopharm Drug Dispos. 1999 ; 20: 233-240 (Pubitemid 30021067)
29. Jiang D, Bai X, Zhang Q, et al. Effects of CYP2C19 and CYP2C9 genotypes on pharmacokinetic variability of valproic acid in Chinese epileptic patients: nonlinear mixed-effect modeling. Eur J Clin Pharmacol. 2009 ; 65: 1187-1193
30. Yukawa E, To H, Ohdo S, Higuchi S, Aoyama T. Population-based investigation of valproic acid relative clearance using nonlinear mixed effects modeling: influence of drug-drug interaction and patient characteristics. J Clin Pharmacol. 1997 ; 37: 1160-1167 (Pubitemid 28076461)